Cargando…

Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer

Albendazole is an anti-helminthic drug that has been shown to exhibit anti-cancer properties, however its activity in head and neck squamous cell cancer (HNSCC) was unknown. Using a series of in vitro assays, we assessed the ability of albendazole to inhibit proliferation in 20 HNSCC cell lines acro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghasemi, Farhad, Black, Morgan, Vizeacoumar, Frederick, Pinto, Nicole, Ruicci, Kara M., Le, Carson Cao Son Huu, Lowerison, Matthew R., Leong, Hon Sing, Yoo, John, Fung, Kevin, MacNeil, Danielle, Palma, David A., Winquist, Eric, Mymryk, Joe S., Boutros, Paul C., Datti, Alessandro, Barrett, John W., Nichols, Anthony C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641066/
https://www.ncbi.nlm.nih.gov/pubmed/29069723
http://dx.doi.org/10.18632/oncotarget.17292
Descripción
Sumario:Albendazole is an anti-helminthic drug that has been shown to exhibit anti-cancer properties, however its activity in head and neck squamous cell cancer (HNSCC) was unknown. Using a series of in vitro assays, we assessed the ability of albendazole to inhibit proliferation in 20 HNSCC cell lines across a range of albendazole doses (1 nM–10 μM). Cell lines that responded to treatment were further examined for cell death, inhibition of migration and cell cycle arrest. Thirteen of fourteen human papillomavirus-negative HNSCC cell lines responded to albendazole, with an average IC(50) of 152 nM. In contrast, only 3 of 6 human papillomavirus-positive HNSCC cell lines responded. Albendazole treatment resulted in apoptosis, inhibition of cell migration, cell cycle arrest in the G2/M phase and altered tubulin distribution. Normal control cells were not measurably affected by any dose tested. This study indicates that albendazole acts to inhibit the proliferation of human papillomavirus-negative HNSCC cell lines and thus warrants further study as a potential chemotherapeutic agent for patients suffering from head and neck cancer.